I'm located in an accurate understanding of what D
Post# of 30028
I have also maintained that back in early 2014 Urano's focus on treating wolframs/diabetes was on "recombinant MANF injections." But, by September of 2014 Urano switched his preference away from "recombinant" to "small molecules" as a method of targeting the endogenous production of MANF within the body. (Which doesn't involve AMBS) He has reaffirmed his targeting of MANF from within the body as recently as 2 weeks ago.
For some reason you and several others here on the mb have consistently misunderstood this! This is not rocket science.